Click to Learn More |
Under the current 340B program, hospitals or covered entities are reimbursed for prescription drugs at a higher rate but are not required to pass the profits on to patients. The dramatic growth of participation in the program has resulted in higher overall costs within the supply chain, some argue.
“The 340B program is an important resource for hospitals serving low-income areas,” Dr Cassidy said. “But too often the program’s discounts are used to pad hospitals’ bottom lines instead of helping disadvantaged patients afford their treatments. This bill will increase transparency and accountability and help ensure these discounts reach patients.”